TVTX Q3 2020 Earnings — Travere Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TVTXTravere Therapeutics, Inc.

$3B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$51M+15.2% YoY

Gross Profit

$50M97.7% margin

Operating Income

-$19M-38.0% margin

Net Income

-$23M-44.1% margin

EPS (Diluted)

$-0.44

QoQ Revenue Growth

+5.6%

Cash Flow

Operating Cash Flow

$7M

Free Cash Flow

-$180,000

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$692M

Total Liabilities

$391M

Stockholders' Equity

$301M

Cash & Equivalents

$200M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$51M	$44M	+15.2%
Gross Profit	$50M	$43M	+16.5%
Operating Income	-$19M	-$34M	+43.6%
Net Income	-$23M	-$36M	+38.2%

Revenue Segments

Tiopronin Products

$28M55%

Bile Acid Products

$23M45%